Small molecules capable of reactivating FMR1 expression in post-mitotic neurons, the primary target cell type responsible for FXS symptomatology, will likely demonstrate an alternative mechanism of action and will be required for inclusion in future targeted screening studies. Here, FMR1 is linked to fragile X syndrome.